

Neogenomics Inc. (NEO)

Nasdaq; other; SIC 8734, Services-Testing Laboratories; CIK 0001077183

Neogenomics Inc. NEO; other	
Grade	C A B C D E middle fifth of 336 graded peers percentile 54.9; sampling error 2.6 points; lower is stronger
Rank	185 of 336
Profitability	C/D percentile 61.3
Solvency	B percentile 28.3
Growth and financing	C/D percentile 58.7
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$1.4B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress
Inputs computable	9 of 14
Graded from	filings received through Feb 17, 2026 234 days before the rescans; latest periodic filing 10-Q received Jul 28, 2026
Last close	\$16.03 2026-10-08; market equity \$2.1B
Price used in grade	None



C, the tortoise

middle fifth of its sector; letters are fifths of the 336 graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: D from Mar 21, 2022, C/D from Feb 21, 2024, D from Mar 21, 2024, C from Feb 21, 2024

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 17, 2026

NeoGenomics, Inc., a Nevada corporation (referred to individually as the "Company" or collectively with its subsidiaries as "NeoGenomics," "we," "us," or "our" in this Annual Report on Form 10-K) is the registrant for SEC reporting purposes. Our common stock is listed on The Nasdaq Stock Market LLC ("Nasdaq") under the symbol "NEO." NeoGenomics provides a wide range of oncology diagnostic testing and consultative services including technical laboratory services and professional interpretation

of laboratory test results by licensed physicians or molecular experts who specialize in pathology and oncology.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 61.3						
Gross profitability		23.1%	27.1%	52.4	289	2025-12-31
Return on invested capital		(10.8%)	10.0%	94.7	151	2025-12-31
Accruals ratio		(7.6%)	(5.9%)	38.6	506	2025-12-31
Gross margin stability, five years		2.7 pts	2.2 pts	59.6	204	2025-12-31
Solvency, sleeve percentile 28.3						
Twelve-month failure probability		not computable	0.04%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		1.46	2.05	48.1	386	2025-12-31
Net debt to EBITDA		not computable	2.52x			EBITDA must exceed \$100,000
Interest coverage		not computable	2.18x			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		4.26x	1.32x	8.5	506	2025-12-31
Growth and financing, sleeve percentile 58.7						
Revenue growth, three-year compound		12.6%	5.1%	26.1	403	2025-12-31
Free cash flow growth, three-year compound		not computable	8.7%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	11.9%			NOPAT must exceed \$100,000
Asset growth, three years		(7.9%)	4.1%	85.1	438	2025-12-31
Net share issuance, one year		1.1%	(0.4%)	64.8	356	2026-02-13

Among 336 peers

other; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
180	Rimini Street, Inc. (RMNI)	53.4	C	fortress balance sheet
181	Union Pacific Corp. (UNP)	53.7	C	
182	Lyft, Inc. (LYFT)	54.0	C	fortress balance sheet
183	Hilton Worldwide Holdings Inc. (HLT)	54.3	C	
184	Arlo Technologies, Inc. (ARLO)	54.6	C	
185	Neogenomics Inc. (NEO) <	54.9	C	
186	Life Time Group Holdings, Inc. (LTH)	55.2	C	
187	United Airlines Holdings, Inc. (UAL)	55.5	C	
188	Equifax Inc. (EFX)	55.8	C	
189	International Seaways, Inc. (INSW)	56.1	C	
190	Delta AIR Lines, Inc. (DAL)	56.4	C	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	132.0%	2.0%	99
Distance from 52-week high	(19.5%)	(26.8%)	61
EBIT to enterprise value	(5.1%)	4.4%	13
Free cash flow yield	(1.1%)	4.1%	21
Book value to price	0.38	0.34	57
Sales to price	0.35	0.70	31
Composite equity issuance, five years	9.4%	(8.8%)	77
Relative strength against the sector, log excess return	0.69	(0.13)	99

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 4 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$145.5M
Operating cash flow, four quarters	\$22.0M
Months of runway	not finite
Days since last periodic filing	73 (10-Q received Jul 28, 2026)
Median daily dollar volume, 63 sessions	\$30.7M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$314.3M	2025-12-31	2026-02-17	10-K	0001077183-26-000010
2	assets	us-gaap:Assets	\$1.4B	2025-12-31	2026-02-17	10-K	0001077183-26-000010
3	operating income	us-gaap:OperatingIncomeLoss	-\$115.9M	2025-12-31	2026-02-17	10-K	0001077183-26-000010
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItems	-\$110.3M	2025-12-31	2026-02-17	10-K	0001077183-26-000010
5	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$2.2M	2025-12-31	2026-02-17	10-K	0001077183-26-000010
6	total debt	us-gaap:LongTermDebt	\$341.9M	2025-12-31	2026-02-17	10-K	0001077183-26-000010

7	book equity	us-gaap:StockholdersEquity	\$836.6M	2025-12-31	2026-02-17	10-K	0001077183-26-000010
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$159.6M	2025-12-31	2026-02-17	10-K	0001077183-26-000010
9	total debt	us-gaap:LongTermDebt	\$541.1M	2024-12-31	2026-02-17	10-K	0001077183-26-000010
10	book equity	us-gaap:StockholdersEquity	\$902.3M	2024-12-31	2026-02-17	10-K	0001077183-26-000010
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$367.0M	2024-12-31	2026-02-17	10-K	0001077183-26-000010
12	net income	us-gaap:NetIncomeLoss	-\$108.0M	2025-12-31	2026-02-17	10-K	0001077183-26-000010
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$5.2M	2025-12-31	2026-02-17	10-K	0001077183-26-000010
14	assets	us-gaap:Assets	\$1.6B	2024-12-31	2026-02-17	10-K	0001077183-26-000010
15	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$727.3M	2025-12-31	2026-02-17	10-K	0001077183-26-000010
16	gross profit	us-gaap:GrossProfit	\$290.1M	2024-12-31	2026-02-17	10-K	0001077183-26-000010
17	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$660.6M	2024-12-31	2026-02-17	10-K	0001077183-26-000010
18	gross profit	us-gaap:GrossProfit	\$244.6M	2023-12-31	2026-02-17	10-K	0001077183-26-000010
19	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$591.6M	2023-12-31	2026-02-17	10-K	0001077183-26-000010
20	gross profit	us-gaap:GrossProfit	\$187.9M	2022-12-31	2025-02-18	10-K	0001077183-25-000028
21	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$509.7M	2022-12-31	2025-02-18	10-K	0001077183-25-000028
22	gross profit	us-gaap:GrossProfit	\$187.1M	2021-12-31	2024-02-20	10-K	0001077183-24-000011
23	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$484.3M	2021-12-31	2024-02-20	10-K	0001077183-24-000011
24	current assets	us-gaap:AssetsCurrent	\$376.3M	2025-12-31	2026-02-17	10-K	0001077183-26-000010
25	current liabilities	us-gaap:LiabilitiesCurrent	\$88.3M	2025-12-31	2026-02-17	10-K	0001077183-26-000010
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$433.8M	2025-12-31	2026-02-17	10-K	0001077183-26-000010
27	liabilities	us-gaap:Liabilities	\$523.3M	2025-12-31	2026-02-17	10-K	0001077183-26-000010
28	depreciation amortization	us-gaap:Depreciation	\$36.1M	2025-12-31	2026-02-17	10-K	0001077183-26-000010
29	operating income	us-gaap:OperatingIncomeLoss	-\$107.7M	2023-12-31	2026-02-17	10-K	0001077183-26-000010
30	interest expense	us-gaap:InterestExpense	\$6.9M	2023-12-31	2024-02-20	10-K	0001077183-24-000011
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$27.0M	2025-12-31	2026-02-17	10-K	0001077183-26-000010
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$7.0M	2024-12-31	2026-02-17	10-K	0001077183-26-000010
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$41.1M	2024-12-31	2026-02-17	10-K	0001077183-26-000010
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$2.0M	2023-12-31	2026-02-17	10-K	0001077183-26-000010
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$28.8M	2023-12-31	2026-02-17	10-K	0001077183-26-000010
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$66.0M	2022-12-31	2025-02-18	10-K	0001077183-25-000028
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$30.9M	2022-12-31	2025-02-18	10-K	0001077183-25-000028
38	current assets	us-gaap:AssetsCurrent	\$596.0M	2024-12-31	2026-02-17	10-K	0001077183-26-000010
39	current liabilities	us-gaap:LiabilitiesCurrent	\$301.2M	2024-12-31	2026-02-17	10-K	0001077183-26-000010
40	assets	us-gaap:Assets	\$1.7B	2023-12-31	2025-02-18	10-K	0001077183-25-000028
41	assets	us-gaap:Assets	\$1.7B	2022-12-31	2024-02-20	10-K	0001077183-24-000011
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	129,812,211	2026-02-13	2026-02-17	10-K	0001077183-26-000010
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	128,461,383	2025-02-11	2025-02-18	10-K	0001077183-25-000028